DDI-DrugBank.d572.s0 >> Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. >> 0-13,28-41,90-98
DDI-DrugBank.d572.s1 >> The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. >> 46-54,59-72
DDI-DrugBank.d572.s2 >> Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. >> 0-7,42-50,70-77
DDI-DrugBank.d572.s3 >> Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. >> 0-7
DDI-DrugBank.d572.s4 >> In a preclinical study in dogs, ezetimibe increased cholesterol in the gallbladder bile. >> 32-40
DDI-DrugBank.d572.s5 >> Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. >> 21-25,32-39
DDI-DrugBank.d572.s6 >> Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. >> 0-10,53-63,96-104
DDI-DrugBank.d572.s7 >> Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. >> 0-10,53-63,96-104
DDI-DrugBank.d572.s8 >> HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. >> 0-27,100-108,135-146,149-159,162-172,175-184,190-200
DDI-DrugBank.d572.s9 >> Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. >> 0-11,24-32,132-143
DDI-DrugBank.d572.s10 >> Patients who take both ezetimibe and cyclosporine should be carefully monitored. >> 23-31,37-48
DDI-DrugBank.d572.s11 >> Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). >> 99-107,271-279
DDI-DrugBank.d572.s12 >> A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). >> 46-54,187-195
DDI-DrugBank.d572.s13 >> There were no statistically significant increases in tumor incidences in drug-treated rats or mice.
DDI-DrugBank.d572.s14 >> No evidence of mutagenicity was observed in vitro in a microbial mutagenicity (Ames) test with Salmonella typhimurium and Escherichia coli with or without metabolic activation.
DDI-DrugBank.d572.s15 >> No evidence of clastogenicity was observed in vitro in a chromosomal aberration assay in human peripheral blood lymphocytes with or without metabolic activation.
DDI-DrugBank.d572.s16 >> In addition, there was no evidence of genotoxicity in the in vivo mouse micronucleus test.
DDI-DrugBank.d572.s17 >> In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). >> 38-46,240-248
DDI-DrugBank.d572.s18 >> Pregnancy Pregnancy Category: C There are no adequate and well-controlled studies of ezetimibe in pregnant women. >> 85-93
DDI-DrugBank.d572.s19 >> Ezetimibe should be used during pregnancy only if the potential benefit justifies the risk to the fetus. >> 0-8
DDI-DrugBank.d572.s20 >> In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of embryolethal effects at the doses tested (250, 500, 1000 mg/kg/day). >> 53-61
DDI-DrugBank.d572.s21 >> In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1000 mg/kg/day (~10 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). >> 254-262
DDI-DrugBank.d572.s22 >> In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). >> 24-32,186-194
DDI-DrugBank.d572.s23 >> Ezetimibe crossed the placenta when pregnant rats and rabbits were given multiple oral doses. >> 0-8
DDI-DrugBank.d572.s24 >> Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. >> 25-33,61-88,91-97,158-166
DDI-DrugBank.d572.s25 >> Reproductive findings occur at lower doses in combination therapy compared to monotherapy.
DDI-DrugBank.d572.s26 >> All HMG-CoA reductase inhibitors are contraindicated in pregnant and nursing women. >> 4-31
DDI-DrugBank.d572.s27 >> When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. >> 5-9,35-61,162-188
DDI-DrugBank.d572.s28 >> Labor and Delivery The effects of ZETIA on labor and delivery in pregnant women are unknown. >> 34-38
DDI-DrugBank.d572.s29 >> Nursing Mothers In rat studies, exposure to total ezetimibe in nursing pups was up to half of that observed in maternal plasma. >> 50-58
DDI-DrugBank.d572.s30 >> It is not known whether ezetimibe is excreted into human breast milk; >> 24-32
DDI-DrugBank.d572.s31 >> therefore, ZETIA should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant. >> 11-15
DDI-DrugBank.d572.s32 >> Pediatric Use The pharmacokinetics of ZETIA in adolescents (10 to 18 years) have been shown to be similar to that in adults. >> 38-42
DDI-DrugBank.d572.s33 >> Treatment experience with ZETIA in the pediatric population is limited to 4 patients (9 to 17 years) in the sitosterolemia study and 5 patients (11 to 17 years) in the HoFH study. >> 26-30
DDI-DrugBank.d572.s34 >> Treatment with ZETIA in children (<10 years) is not recommended. >> 15-19
DDI-DrugBank.d572.s35 >> Geriatric Use Of the patients who received ZETIA in clinical studies, 948 were 65 and older (this included 206 who were 75 and older). >> 43-47
DDI-DrugBank.d572.s36 >> The effectiveness and safety of ZETIA were similar between these patients and younger subjects. >> 32-36
DDI-DrugBank.d572.s37 >> Greater sensitivity of some older individuals cannot be ruled out.
